Back to Search

BRIAN LUM, MD

MD

Family Medicine Physician

NPI: 1245359132IndividualAccepts Medicare

Specialties, Licenses & Credentials

Family Medicine PhysicianPrimary

Family Medicine

Code: 207Q00000X

20203(MS)2019-00062(NC)52174(TN)126620(AK)28309(SC)

CMS Specialties

PrimaryFAMILY PRACTICE

Education

UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE

Class of 2005

Research & Publications (20)

Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors.
PMID 19415281·Cancer Chemother Pharmacol·2009
3-trial
Effect of diabetic retinopathy and panretinal photocoagulation on retinal nerve fiber layer and optic nerve appearance.
PMID 19597104·Arch Ophthalmol·2009
4-observational
A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach.
PMID 19299235·Clin Breast Cancer·2009
3-trial
Clinical pharmacokinetics of bevacizumab in patients with solid tumors.
PMID 18205003·Cancer Chemother Pharmacol·2008
8-other
Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals.
PMID 18176118·Anticancer Drugs·2008
2-rct
The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition.
PMID 18000659·Eur J Clin Pharmacol·2008
2-rct
Pharmacokinetics and safety of bevacizumab administered in combination with cisplatin and paclitaxel in cynomolgus monkeys.
PMID 17549476·Cancer Chemother Pharmacol·2008
7-preclinical
Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer.
PMID 16890575·Clin Pharmacol Ther·2006
3-trial
Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis.
PMID 16715358·Pharm Res·2006
4-observational
Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects.
PMID 16490804·J Clin Pharmacol·2006
3-trial

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Contact & Hours

Address
811 PENDLETON ST STE 10
GREENVILLE, SC 29601

Quick Facts

NPI
1245359132
Entity Type
Individual
Gender
Male
Medicare
Accepted
Specialties
5
Locations
1
Years in Practice
21
Publications
20

Are you this provider?

Claim Your Profile